Bianco Domenico, Armstrong P Jane, Washabau Robert J
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
J Vet Intern Med. 2007 Jul-Aug;21(4):694-9. doi: 10.1892/0891-6640(2007)21[694:tositw]2.0.co;2.
Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura.
The purpose of this study was to describe adverse effects and benefit of hIVIG in addition to conventional immunosuppressive therapy in dogs with severe IMT.
Five client-owned dogs with severe primary IMT.
Case series. The hospital database was searched for dogs with primary IMT treated with hIVIG.
No adverse effects were noted during or after hIVIG infusion in any treated dog. Over a 6-month follow-up, all dogs were clinically normal when using conventional immunosuppressive therapy. Human IVIG was administered 3 days after initiation of immunosuppressive therapy in 4 dogs, and, after 2 days, in 1 dog. In all dogs, the mean platelet counts pre- and 24 hours post-hIVIG infusion (0.28-0.76 g/kg) were 2,500/pL and 50,600/microL (62,750/microL for the 4 responders), respectively. One dog failed to respond as promptly to hIVIG (0.34 g/kg), and the platelet count increased to 66,000/microL after 9 days of immunosuppressive therapy. The mean duration of hospitalization post-hIVIG in all 5 dogs was 1.8 days (12 hours for responders), and the mean total length of hospitalization was 4.6 days (3.5 days for responders). Active hemorrhage resolved and no packed red blood cell transfusions were required after hIVIG infusion for responders.
Human IVIG was well tolerated and appeared to be associated with rapid platelet count recovery and amelioration of clinical signs in most dogs with IMT.
糖皮质激素联合或不联合其他免疫疗法是重度免疫介导性血小板减少症(IMT)犬的初始治疗选择。大多数接受治疗的犬在开始治疗后5至7天内血小板计数会有所改善,但在出现反应之前,出血并发症经常发生。人静脉注射免疫球蛋白(hIVIG)可阻断犬单核吞噬细胞上的Fc受体;它用于特发性血小板减少性紫癜患者。
本研究的目的是描述hIVIG在重度IMT犬常规免疫抑制治疗基础上的不良反应和益处。
5只客户拥有的重度原发性IMT犬。
病例系列研究。在医院数据库中搜索接受hIVIG治疗的原发性IMT犬。
在任何接受治疗的犬中,hIVIG输注期间或之后均未观察到不良反应。在6个月的随访中,所有犬在使用常规免疫抑制治疗时临床均正常。4只犬在免疫抑制治疗开始后3天给予hIVIG,1只犬在2天后给予。所有犬在hIVIG输注前(0.28 - 0.76 g/kg)和输注后24小时的平均血小板计数分别为2,500/μL和50,600/μL(4只反应者为62,750/μL)。1只犬对hIVIG(0.34 g/kg)反应不迅速,在免疫抑制治疗9天后血小板计数升至66,000/μL。所有5只犬hIVIG输注后的平均住院时间为1.8天(反应者为12小时),平均总住院时间为4.6天(反应者为3.5天)。反应者在hIVIG输注后活动性出血得到缓解,无需输注浓缩红细胞。
hIVIG耐受性良好,在大多数IMT犬中似乎与血小板计数快速恢复和临床症状改善有关。